With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
The top analyst upgrades, downgrades and other research calls from Thursday include Biogen, Cabot Oil & Gas, CenturyLink, NetApp, Square, T-Mobile and Wix.com.
The top analyst upgrades, downgrades and other research calls from Tuesday include Altice USA, CVS Health, Exxon, Lowe's, T-Mobile, Sprint and Under Armour.
The top analyst upgrades, downgrades and other research calls from Monday include BlackBerry, BP, Camping World, Deere, GrubHub, KLA-Tencor, Teva Pharmaceutical and Zions Bancorp.
The top analyst upgrades, downgrades and initiations seen on Monday include AK Steel, Amazon.com, AngloGold Ashanti, Bank of America, General Electric, Walt Disney and Xilinx.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Carnival, Facebook, Freeport-McMoRan, Motorola Solutions and Procter & Gamble.
Esperion Therapeutics and a few other biopharma stocks made massive runs on Monday morning.
The top analyst upgrades, downgrades and initiations seen on Friday, January 6, include Cognizant Technology Solutions, Etsy, GoPro, Illumina, Shake Shack and Travelers Companies.
With the busiest earnings week behind us, it appears some of the restriction windows at major U.S. corporations are starting to open up a little.
Nektar Therapeutics plans to price 13 million shares at $13.50 for a secondary offering valued up to almost $202 million.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Monday, February 8 include Athenahealth, Baker Hughes, Cisco, LinkedIn, Orbital-ATK and Tableau Software.
The analysts at Cowen have calculated the buys and sells in the NYSE Arca Biotechnology Index based on the holdings in the First Trust Biotechnology ETF.
The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight.
On the close Friday, the NYSE Arca Biotechnology Index is set for a rebalance. These four stocks that could see the highest amount of share count buying.
Lee Jackson The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top stocks started with a rating of Buy at Jefferies.
